Dr
Nicola
Elliott

Senior Patent Attorney

London Office

Chemistry

Telephone. +44(0) 207 776 5100
Email. [email protected]

Experience

Nicola's patent practice is principally focussed on chemical inventions, with particular experience in the fields of pharmaceutical and veterinary medicine, agrochemicals, subsea technologies, petrochemicals, batteries and ink technologies.

Nicola has considerable experience in securing patent protection in a range of chemical technologies. As well as prosecuting patent applications in Europe and the UK, Nicola is also involved in the management of international patent portfolios covering a wide variety of jurisdictions. She has also drafted patent applications in various technical fields, and has experience in oppositions and appeals matters at the European Patent Office.

Nicola graduated from the University of Durham in the UK with a first class honours degree in chemistry in 2003. She subsequently obtained a PhD in physical chemistry from the University of Bristol also in the UK. Her PhD research involved the study of the detailed electronic structure of various small molecules, using high resolution laser spectroscopy.

Nicola joined the patent profession in 2007, qualifying as a European Patent Attorney in 2011 and a Chartered Patent Attorney in 2012. Nicola joined the London office of HGF in September 2013, having previously worked elsewhere in private practice.

Qualifications

Patent Attorney

Chartered (UK)
European


MCHEM

University of Durham

PHD

University of Bristol

Related News

Artificial intelligence inventions in healthcare – can you patent them in Europe?

Artificial Intelligence (AI) has moved from the realm of science fiction firmly into the mainstream of technological innovation. Trained AI models in some cases are able to perform data analysis …

Read article

Patenting digital mental health

Mental health and behavioural disorders have a profound impact on wellbeing worldwide, with an estimated 13% of the global population suffering from a mental health or substance use disorder [1]. …

Read article

Patenting antibodies in the US and Europe

Is the USPTO now stricter than the EPO on antibody claims? A consideration of recent developments from both sides of the pond. Patent protection for monoclonal antibodies, bispecific antibodies and …

Read article

Patentability of Simulations in Europe

Simulations offer a powerful tool in modern-day engineering. Subjecting designs to initial testing in a simulated environment will, for many designs, reduce costs owing to reduced needs to produce and …

Read article

Blockbuster blood thinning patent revoked

Summary Mr Justice Meade has revoked Bristol Myers Squibb’s (BMS) European patent No. EP1427415 (EP’415) and corresponding supplementary protection certificate (SPC) that relate to the compound Apixaban (ELIQUIS) for lack …

Read article
Event - 10th May 2022

The HGF IP in Healthcare Conference 2022

After a challenging couple of years, we are delighted to invite you to join us for HGF’s eighth annual IP in Healthcare Conference. We will review the latest intellectual property …

Event details
Event - 10th May 2022

HGF UPC events in Germany and Austria 2022

HGF is holding a webinar and an in-person event covering the UPC in Germany and Austria this Spring. The provisional phase of the Unified Patent Court (UPC) is now underway …

Event details
Event - 23rd March 2022

HGF webinar: Getting your first filing right

HGF hosted a webinar on Wednesday 23rd March on Getting your first filing right. One of the most often asked questions of patent attorneys is: “when should we file?” Both …

Event details

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.